Life
Understanding the BALANCE Model for GLP-1s in Medicare and Medicaid
This brief outlines the current coverage of GLP-1s in Medicare and Medicaid, focusing on CMS's BALANCE model aimed at enhancing access and reducing costs.
Editorial Staff
1 min read
The Centers for Medicare & Medicaid Services (CMS) is currently overseeing the coverage of GLP-1 medications within Medicare and Medicaid programs. This coverage is crucial for managing diabetes and obesity.
To address access and affordability, CMS is implementing the BALANCE model, which comprises temporary demonstration programs designed to evaluate the effectiveness of GLP-1s in these populations.
The BALANCE model aims to provide insights into how expanded access to GLP-1s can lead to better health outcomes while simultaneously working to lower associated costs.